Standard BioTools

Standard BioTools Receivables

The Accounts Receivable of Standard BioTools (LAB) as of Sep 21, 2026 is 19.66 M USD. In the previous year, Accounts Receivable was 17.30 M USD — a change of 13.64% (higher).

Receivables

19.66 MUSD

YoY

13.64%

Last updated:

Accounts Receivable of Standard BioTools is 2026 19.66 M USD. Accounts Receivable of Standard BioTools was 2025 17.30 M USD. It decreases by 13.64% higher compared to the previous year.

The Standard BioTools Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
14.60 M USD
Jan 1, 2017
15.00 M USD
Jan 1, 2018
16.70 M USD
Jan 1, 2019
19.00 M USD
Jan 1, 2020
25.40 M USD
Jan 1, 2021
18.30 M USD
Jan 1, 2022
17.30 M USD
Jan 1, 2023
19.66 M USD
The Standard BioTools Receivables history
YEARReceivablesYoY
19.66 MUSD+13.64%
17.30 MUSD-5.46%
18.30 MUSD-27.95%
25.40 MUSD+33.68%
19.00 MUSD+13.77%
16.70 MUSD+11.33%
15.00 MUSD+2.74%
14.60 MUSD-42.75%
25.50 MUSD+13.84%
22.40 MUSD
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Accounts Receivable of Standard BioTools is 19.66 M USD in 2026.

Accounts Receivable of Standard BioTools changed from 17.30 M USD to 19.66 M USD, representing a 13.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools